{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:12Z","timestamp":1761901332968,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.msard.2018.03.021","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T15:15:54Z","timestamp":1522336554000},"page":"87-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab"],"prefix":"10.1016","volume":"22","author":[{"given":"Martin W.","family":"H\u00fcmmert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Deppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bronzlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.03.021_bib1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2169\/internalmedicine.55.6649","article-title":"Progressive multifocal leukoencephalopathy localized in the cerebellum and brainstem associated with idiopathic CD4(+) T lymphocytopenia","volume":"55","author":"Aotsuka","year":"2016","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2018.03.021_bib2","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.0402653101","article-title":"Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta","volume":"101","author":"Bielekova","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2018.03.021_bib3","first-page":"18","article-title":"Natalizumab in multiple sclerosis: long-term management","author":"Clerico","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2018.03.021_bib4","first-page":"119","article-title":"Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis","volume":"10","author":"Cohan","year":"2016","journal-title":"Biologics"},{"key":"10.1016\/j.msard.2018.03.021_bib5","doi-asserted-by":"crossref","first-page":"e00671","DOI":"10.1002\/brb3.671","article-title":"Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation","volume":"7","author":"Gonzalez-Suarez","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.msard.2018.03.021_bib6","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus Interferon Beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.03.021_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal","volume":"23","author":"Larochelle","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.03.021_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clim.2011.10.008","article-title":"Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis","volume":"142","author":"Martin","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2018.03.021_bib9","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.03.021_bib10","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/WNL.0b013e3182a84179","article-title":"Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient","volume":"81","author":"Tortorella","year":"2013","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:34Z","timestamp":1761900154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":10,"alternative-id":["S2211034818301172"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.03.021","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}